Demystifying Health Economics: A Practical Guide for Startups

Health economics can be a daunting subject, but understanding its principles is crucial for startups looking to navigate funding, investment, and strategic growth in the healthcare sector.
Join us for an insightful masterclass where leading experts break down key concepts and provide practical strategies to help you integrate health economics into your business model.

What You Will Learn:

Grasp the fundamentals of health economics and its relevance to startups.
Identify key stages where health economics is critical to business strategy.
Understand when to apply health economic considerations and why they matter.
Gain a practical guide to developing your own health economic model.
Learn from real-world examples of startups integrating health economics on lean budgets.
Leverage Medical Affairs to enhance health economic value and strategic positioning.

Agenda:

11:30am: Registration + light lunch networking
12:10pm: Masterclass and Guest Seminar
1:05pm: Q&A & Panel Discussion
1:50pm: Wrap up
2:00pm: Event concludes

Meet the Experts:

Colin Denver - Facilitator
Former CEO - SpeeDx
Colin is an experienced executive with a strong background in diagnostics and healthcare innovation. As the former CEO of SpeeDx, he led the company through strategic growth, commercialisation, and global market expansion. His expertise in medical technology and business development makes him an ideal facilitator for this discussion on health economics and startup strategy.

Penny Reeves - Keynote Speaker
Associate Director, Health Economics and Impact - HMRI
With over 25 years of experience as an applied health economist, Penny has worked across pharmaceutical, biotech, and medical research sectors. She has held senior advisory roles in both Australian and UK government bodies and is a Conjoint Associate Professor with the University of Newcastle. Currently serving as Chief of Research Development at HMRI, Penny specialises in health economic analyses, funding strategies, and bridging the gap between innovation and commercial success.

Jennifer Holland - Panel Member
Business Development Manager (HMRI), Former CEO and Entrepreneur
Jennifer has over 15 years of experience in healthcare business development, technology innovation, and patient care solutions. As a former CEO and entrepreneur, she has firsthand experience in translating innovative ideas into successful health solutions. At HMRI, she connects research with commercialisation opportunities, helping startups navigate the complexities of health economics and funding.

Matthew Britland - Panel Member
Medical Director - MedWise Consulting
Matt is an experienced Medical Affairs Director with expertise in pharmaceutical medicine, oncology, and haematology. As the Co-Founder and Medical Director at MedWise Consulting, he focuses on leveraging Medical Affairs to drive strategic positioning and health economic value. He holds an MMedSc in Pharmaceutical Medicine and is pursuing a DrPH, researching the impact of Medical Affairs on the Quality Use of Medicines (QUM) and patient outcomes.

This panel will be facilitated by Colin Denver.

-----------

Don't miss this opportunity to gain valuable insights from industry experts and network with fellow health tech innovators.

Register now to secure your spot in this must-attend masterclass for health tech entrepreneurs looking to amplify their presence in the market!

Cicada Innovations is proud to be collaborating with the Westmead Health & Innovation District, Australia’s fastest-growing health and innovation precinct, for this commercialisation masterclass series. These masterclasses are to help bridge the gap between research and commercialisation.

Find out more about the Cicada HealthTech Hub

The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.